Announcements
Bones, Joints, and Muscles
The National Arthritis and Musculoskeletal and Skin Diseases Advisory Council is a congressionally mandated NIH peer review group that meets three times a year. It provides advice to NIAMS on broad policy issues and makes recommendations on research proposals. It comprises scientific and lay members who have expertise in the mission areas of the Institute. The morning session of the advisory council meeting includes a report from the director of NIAMS, and is open to the public. More
Next StepsIf you have questions about attending the meeting, or would like directions, please send an e-mail to NIAMSInfo@mail.nih.gov. Attendees do not need to preregister. As soon as the agenda is available, a link will appear at www.niams.nih.gov/ne/mcw/agenda.htm. Visitors to the NIH campus in Bethesda, Maryland, should bring a photo ID and allow additional time for security procedures. All vehicles will be inspected and visitor badges issued at the NIH Gateway vehicle inspection station. Visitor badges will be issued to pedestrians at either the NIH Gateway Center, at Metro (24/7), or the NIH West Visitor Center, Old Georgetown Road and South Drive (5 a.m. to 9 p.m. only). Call 301-594-6677 for more information, or visit the Web site at www.nih.gov/about/visitor/index.htm.
Community Outreach
Young scientists are encouraged to apply for Intramural NIAID Research Opportunities (INRO), a free 5-day program to be held in early February 2006. Designed for students from populations underrepresented in science, INRO brings together students from across the country who are considering a career in biomedical research in the areas of allergy, immunology, or infectious diseases.Students selected to attend INRO 2006 will:
Next StepsPlease visit the NIAID Web site for more details about student eligibility, highlights of last year's INRO program agenda, student testimonies from past programs, and detailed information about the application process at www.niaid.nih.gov/dir/otsep/inro/description.htm. You may reach the INRO coordinator at inro@niaid.nih.gov.
Infectious Disease
Seniors' Health
The purpose of the Alzheimer’s Disease Neuroimaging Initiative is to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). This information will aid future clinical trials by providing a standard assessment tool to measure the effects of treatments being studied.The study will take place at approximately 50 sites across the U.S. and Canada. Investigators will recruit about 800 adults, aged 55 to 90, to participate in the research—approximately 200 cognitively normal older individuals will be followed for 3 years, 400 people with MCI will be followed for 3 years, and 200 people with early AD will be followed for 2 years.The Alzheimer’s Disease Neuroimaging Initiative is a $60 million, 5-year public-private partnership to test whether brain imaging technology such as serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of MCI and early AD. The study will compare neuroimaging with biological and clinical information from study participants in an attempt to track the progress of memory loss from its earliest stages. Neuroimaging research has suggested that PET or MRI may serve as a more sensitive and consistent measure of disease progression than the neuropsychological and cognitive assessments now used in research. Ultimately, standardizing the methodology for neuroimaging could provide a better way to compare results from different trials and studies, a major goal of the initiative. More
Next StepsPeople interested in participating in the study should call the NIA’s Alzheimer’s Disease Education and Referral Center at 1-800-438-4380. Additional information is available at www.clinicaltrials.gov and www.alzheimers.org/clintrials/news.htm.
The Alzheimer’s disease Genetics Study is a nationwide study to find the genes that play a role in late-onset Alzheimer’s Disease (AD). Scientists hope this all-out effort will speed the discovery of the genes that increase the risk of AD in later life and of ways to prevent it. The AD Genetics Study is seeking families with two or more living siblings who have been diagnosed with AD. Volunteers should be aged 60 or older. A third family member also is needed—this family member may be either affected or unaffected by AD. Local sites will collect clinical and demographic information from the families for the National Cell Repository (NCRAD) at Indiana University. All information will be kept confidential. This study does not provide medical treatment. More
Next StepsPeople interested in participating in this study can call the toll-free NCRAD number, 1-800-526-2839, for more information. Study sites are located throughout the United States, and arrangements can be made for eligible families who do not live near a participating site. Additional information can be found at www.clinicaltrials.gov and www.alzheimers.org/clintrials/news.htm.
Visit MedlinePlus for consumer-friendly health information you can trust from the National Library of Medicine at NIH.
The NIH Public Bulletin is published monthly. If you would like to be notified when new issues are posted, please subscribe to the Bulletin listserv.
[ Q&A About NIH | Jobs at NIH | Visitor Information | FOIA ] [ Telephone & Service Directory | Employee Information | Información en español ]
[ Contact Us | Privacy Notice | Disclaimer | Accessibility | Site Map | Search ]
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892
Department of Health and Human Services
